1,4-dihydropyridine has been researched along with Acute Confusional Senile Dementia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chabchoub, F; Iriepa, I; Ismaili, L; Jóźwiak, K; Maj, M; Malek, R; Marco-Contelles, J; Martin, H; Moraleda, I; Wnorowski, A | 1 |
| Bonet, A; Borges, F; Daniel, S; Ismaili, L; Jóźwiak, K; Maj, M; Marco-Contelles, J; Martin, H; Pachòn Angona, I; Refouvelet, B; Silva, TB; Wnorowski, A | 1 |
| Azzouz, R; Bailly, L; Gembus, V; Levacher, V; Papamicaël, C; Peauger, L; Petit, E; Ţînţaş, ML | 1 |
| Edraki, N; Firuzi, O; Javidnia, K; Miri, R; Razzaghi-Asl, N | 1 |
| Dhanjal, JK; Goyal, M; Goyal, S; Grover, A; Hamid, R; Tyagi, C | 1 |
| Bálind, Á; Balogh, G; Bernáth, S; Blundell, KL; Frank, Z; Fülöp, F; Hooper, PL; Horváth, I; Hunya, Á; Kasza, Á; Penke, B; Prodromou, C; Sántha, M; Török, Z; Vigh, L; Zeiler, HJ | 1 |
| Beitnere, U; Jansone, B; Kadish, I; Klusa, V; Pajuste, K; Plotniece, A; van Groen, T | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Broccatelli, F; Budriesi, R; Carosati, E; Chiarini, A; Cruciani, G; Ioan, P; Micucci, M; Zhorov, BS | 1 |
| Arranz-Tagarro, JA; Calvo-Gallardo, E; Fernández-Morales, JC; García, AG; Maroto, M; Padín, JF | 1 |
| Bihel, F; Garino, C; Kraus, JL; Laras, Y; Pietrancosta, N; Quéléver, G; Sheha, M; Wolfe, MS | 1 |
| de Los Ríos, C; García, AG; Guglietta, A; León, R; López, MG; Marco-Contelles, J; Terencio, J; Villarroya, M | 1 |
2 review(s) available for 1,4-dihydropyridine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 2): action in other targets and antitargets.
Topics: Alzheimer Disease; Animals; Antitubercular Agents; Atherosclerosis; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydropyridines; Drug Resistance, Multiple; Humans; Platelet Activating Factor; Tuberculosis | 2012 |
Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for Alzheimer's disease.
Topics: Alzheimer Disease; Apoptosis; Calcineurin; Calcium; Calcium Channels; Calpain; Dihydropyridines; Free Radicals; Humans; Mitochondria; Neurons; Polyphenols; Sodium | 2012 |
10 other study(ies) available for 1,4-dihydropyridine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Multi-target 1,4-dihydropyridines showing calcium channel blockade and antioxidant capacity for Alzheimer's disease therapy.
Topics: Alzheimer Disease; Antioxidants; Calcium; Calcium Channel Blockers; Calcium Channels; Dihydropyridines; Humans; Melatonin; Neuroblastoma; Nimodipine; Tumor Cells, Cultured | 2019 |
Design, Synthesis and Biological Evaluation of New Antioxidant and Neuroprotective Multitarget Directed Ligands Able to Block Calcium Channels.
Topics: Alzheimer Disease; Antioxidants; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Line, Tumor; Dihydropyridines; Humans; Ligands; Monoamine Oxidase Inhibitors; Neuroprotection; Neuroprotective Agents; Nimodipine | 2020 |
Access to Highly Enantioenriched Donepezil-like 1,4-Dihydropyridines as Promising Anti-Alzheimer Prodrug Candidates via Enantioselective Tsuji Allylation and Organocatalytic Aza-Ene-Type Domino Reactions.
Topics: Alzheimer Disease; Catalysis; Cyclization; Dihydropyridines; Donepezil; Prodrugs; Stereoisomerism | 2018 |
Inhibitors of Alzheimer's BACE-1 with 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridine structure.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Crystallography, X-Ray; Dihydropyridines; Enzyme Inhibitors; Humans; Structure-Activity Relationship | 2015 |
Development of dual inhibitors against Alzheimer's disease using fragment-based QSAR and molecular docking.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Binding Sites; Combinatorial Chemistry Techniques; Dihydropyridines; GPI-Linked Proteins; Humans; Models, Molecular; Molecular Docking Simulation; Protein Binding; Quantitative Structure-Activity Relationship | 2014 |
Dihydropyridine Derivatives Modulate Heat Shock Responses and have a Neuroprotective Effect in a Transgenic Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Cell Line, Tumor; Dendritic Spines; Dihydropyridines; Disease Models, Animal; Gene Expression Regulation; Heat-Shock Proteins; Humans; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neuroblastoma; Neuroprotective Agents; Presenilin-1; tau Proteins | 2016 |
Memory-enhancing and brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer's disease transgenic female mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Anxiety Agents; Blood-Brain Barrier; Calcium; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Female; GABAergic Neurons; Glutamate Decarboxylase; Gyrus Cinguli; Hippocampus; Male; Maze Learning; Memory; Mice; Mice, Transgenic; Neuronal Plasticity; Up-Regulation; Vesicular Inhibitory Amino Acid Transport Proteins | 2016 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Substituted thiazolamide coupled to a redox delivery system: a new gamma-secretase inhibitor with enhanced pharmacokinetic profile.
Topics: Alzheimer Disease; Amides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Biological Availability; Blood-Brain Barrier; Dihydropyridines; Drug Delivery Systems; Endopeptidases; Enzyme Inhibitors; Humans; Male; Molecular Structure; Nicotinic Acids; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Thiazoles | 2005 |
Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Calcium; Calcium Channels; Cell Proliferation; Cells, Cultured; Dihydropyridines; Eels; Humans; Hydrogen Peroxide; L-Lactate Dehydrogenase; Neuroblastoma; Neuroprotective Agents; Structure-Activity Relationship; Tacrine | 2006 |